InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.28
(
0.00%
)
Bitcoin
66,503.39
(
0.47%
)
Post# of 23619
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

RPh1

Send PM Follow Ignore
Followers 6
Posts 857
Boards Moderated 0
Alias Born 09/17/2019

RPh1

Re: None

Friday, 12/18/2020 9:28:57 AM

Friday, December 18, 2020 9:28:57 AM

Post# of 23619
Easy to make the connection. Vilacto Bio wants to be the "GO to partner" for their nanoparticle drug delivery.
Cantabio's mission statement under their pipeline reads

Cantabio is constantly searching for complementary technologies and R&D partnerships to complement the companies’ core scientific and technological intellectual property and capabilities. Cantabio has an on-going policy of review and acquisition of complementary intellectual property, whilst also pursing out-licensing opportunities of its selected therapeutic projects.

Hard to not believe there is something here especially with the links on VIBI website

Imho
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up